Healthcare / Medical DevicesNasdaqGS
$4.24
+0.05 (+1.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $454000.00 · quality 45.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$548M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-19.5%
↓Gross Margin
51.8%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
+16.8%
FCF CAGR
—
FCF margin
-4.4%
FCF / Net income
0.13x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $201.5M · net income $-66.5M · FCF $-8.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $201.5M | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M | $92.8M |
| Net Income | $-66.5M | $-66.5M | $-6.0M | $-12.1M | $2.6M | $3.0M | $19.4M |
| EBITDA | $-17.4M | $-17.4M | $-10.0M | $-4.4M | $9.5M | $10.4M | $14.3M |
| EPS | -0.52 | -0.52 | -0.05 | -0.09 | 0.02 | 0.00 | 0.10 |
| Gross Margin | 51.8% | 51.8% | 55.4% | 56.7% | 61.6% | 61.9% | 55.7% |
| Operating Margin | -20.0% | -20.0% | -10.2% | -14.4% | -1.1% | 7.2% | 14.7% |
| Net Margin | -33.0% | -33.0% | -3.0% | -6.3% | 1.6% | 2.4% | 20.9% |
| Balance Sheet | |||||||
| Debt/Equity | 0.07 | 0.07 | 0.04 | 0.04 | 0.04 | — | — |
| Current Ratio | 4.69 | 4.69 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-8.9M | $-8.9M | $21.6M | $454000.00 | $-22.1M | $266000.00 | $13.6M |
| Returns | |||||||
| ROE | -19.5% | -19.5% | -1.5% | -3.1% | 0.6% | 0.7% | -121.1% |
| Valuation | |||||||
| P/E | — | — | — | — | 542.00 | — | — |
| EV/EBITDA | — | — | — | — | 128.90 | — | — |
| P/B | 1.58 | 1.58 | 2.25 | 2.68 | 3.53 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 0.5% | 0.5% | 3.9% | 17.7% | — | 37.8% | — |
| EPS Growth | -940.0% | -940.0% | 42.3% | -533.4% | — | -100.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+53.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.52
Residual
+53.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.